Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Heart

• Publication date

  2005-01-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/hrt.2003.031310PMID 15657223PMCID PMC1768679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic effects of trimetazidine on ergometric parameters in effort angina

  2004cited by this paper
• Inflammation and Atherosclerosis

  2004cited by this paper
• Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

  2003cited by this paper
• Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

  2003cited by this paper
• C-reactive protein in acute myocardial infarction: association with heart failure.

  2003cited by this paper
• Cardiovascular Diabetology BioMed Central Original Investigation

  2003cited by this paper
• Persistent Infarct–Related Artery Occlusion Is Associated With an Increased Myocardial Apoptosis at Postmortem Examination in Humans Late After an Acute Myocardial Infarction

  2002cited by this paper
• Inflammation and Atherosclerosis

  2002cited by this paper
• C‐reactive protein as a predictor of improvement and readmission in heart failure

  2002cited by this paper
• Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy.

  2001cited by this paper
• The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

  2000cited by this paper
• Metabolic derangement in ischemic heart disease and its therapeutic control.

  1998cited by this paper
• Effects of Trimetazidine on Metabolic and Functional Recovery of Postischemic Rat Hearts

  1998cited by this paper
• Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease.

  1998cited by this paper
• Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon.

  1997cited by this paper
• The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

  1994cited by this paper
• Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.

  1994cited by this paper
• Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.

  1993cited by this paper
• Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome.

  1993cited by this paper
• Paradoxical decrease in circulating neuropeptide Y-like immunoreactivity during mild orthostatic stress in subjects with and without congestive heart failure.

  1993cited by this paper
• Trimetazidine Inhibits Neutrophil Accumulation After Myocardial Ischaemia and Reperfusion in Rabbits

  1993cited by this paper
• Acute effects of trimetazidine on ergometric parameters in effort angina

  1990cited by this paper
• Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.

  1990cited by this paper
• Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats.

  1988cited by this paper
• Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis

  1988cited by this paper
• Constrictive Pericarditis

  1953cited by this paper

• Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review

  2025cites this paper
• Progress of nanomaterials in the treatment of ischemic heart disease.

  2025cites this paper
• Metabolism and bioenergetics in the pathophysiology of organ fibrosis.

  2024cites this paper
• Human cardiac metabolism.

  2024cites this paper
• Impact of Trimetazidine on the Incident Heart Failure After Coronary Artery Revascularization

  2023cites this paper
• Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets

  2023cites this paper
• Exploring the effects and mechanisms of Guizhigancao Decoction on heart failure using an integrated approach based on experimental support and network pharmacology strategy

  2023cites this paper
• Effects of Trimetazidine on Cardiac Function in Adult Cyanotic Congenital Heart Disease Patients: Protocol for a 3-Month Multicenter, Randomized, Double-Blind Controlled Trial.

  2023cites this paper
• Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure

  2023cites this paper
• Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis

  2023cites this paper
• Aspects of myocardial heterogeneity in assessment its remodeling

  2022cites this paper
• Sorting‐free metabolic profiling uncovers the vulnerability of fatty acid β‐oxidation in in vitro quiescence models

  2022cites this paper
• Trimetazidine improves left ventricular global longitudinal strain value in patients with heart failure with reduced ejection fraction due to ischemic heart disease.

  2022cites this paper
• Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition

  2022cites this paper
• Trimetazidine Alleviates Postresuscitation Myocardial Dysfunction and Improves 96‐Hour Survival in a Ventricular Fibrillation Rat Model

  2022cites this paper
• Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies

  2022cites this paper
• Trimetazidine has Promising Preventive Effects on Experimental Chronic Pancreatitis Rat Model.

  2022cites this paper
• Trend of Galectin-3 Levels in Patients with Non-ST-Elevation and ST-Elevation Myocardial Infarction

  2022cites this paper
• Efficacy of trimetazidine - an inhibitor of free fatty acids oxidation in the treatment of patients with stable angina pectoris and heart failure.

  2021cites this paper
• Ketone Therapy for Heart Failure: Current Evidence for Clinical Use.

  2021cites this paper
• Ranolazine, But not Trimetazidine, Influences Markers of Inflammation in Patients with Stable Coronary Artery Disease

  2021cites this paper
• Trimetazidine Therapy in Coronary Artery Disease: The Impact on Oxidative Stress, Inflammation, Endothelial Dysfunction, and Long-Term Prognosis

  2021cites this paper
• Für Sie gelesen: Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis

  2020cites this paper
• Switching from Fatty Acid Oxidation to Glycolysis Improves the Outcome of Acute‐On‐Chronic Liver Failure

  2020cites this paper
• Obesity, Hypertension, and Cardiac Dysfunction

  2020cites this paper
• Modulation of Cardiac Metabolism in Heart Failure

  2019cites this paper
• Cardiovascular Diseases and Hypertension

  2019cites this paper
• Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy

  2018cites this paper
• AMPK: a therapeutic target of heart failure—not only metabolism regulation

  2018cites this paper
• Metabolic Modulation of Cardiac Metabolism in Heart Failure.

  2018cites this paper
• Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure.

  2018cites this paper
• Effects of Post Ischemia-Reperfusion Treatment with Trimetazidine on Renal Injury in Rats: Insights on Delayed Renal Fibrosis Progression

  2018cites this paper
• МИОКАРДИАЛЬНЫЙ ЦИТОПРОТЕКТОР ТРИМЕТАЗИДИН МВ – ПРЕПАРАТ, ПОВЫШАЮЩИЙ ЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ И ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА

  2017cites this paper
• Trimetazidine in conditions other than coronary disease, old drug, new tricks?

  2017cites this paper
• Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application.

  2017cites this paper
• Harnessing Cardiac Energetics in the Treatment of Heart Failure

  2016cites this paper
• Congenital Aortic Stenosis in a Fetus: A Case Report and Review of Syndromic Associations

  2016cites this paper
• The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines.

  2016cites this paper
• Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.

  2016cites this paper
• Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result

  2016cites this paper
• Cardiac Metabolism – The Link to Clinical Practice

  2016cites this paper
• An evaluation of trimetazidine as a therapeutic intervention in a newly established ex vivo mouse model of acute heart failure

  2016cites this paper
• A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine

  2016cites this paper
• Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches.

  2016cites this paper
• Effect of trimetazidine on acute and sub-acute models of inflammation in male wistar rats

  2016cites this paper
• Metabolic Therapy in Heart Failure.

  2015cites this paper
• Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis

  2015cites this paper
• Trimetazidine and Cardioprotection

  2015influential citation
• [Unsolved problems of cytoprotective therapy in patients with coronary heart disease].

  2015cites this paper
• Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.

  2015cites this paper
• The Effect of Trimetazidine Added to Pharmacological Treatment on All-Cause Mortality in Patients with Systolic Heart Failure

  2015cites this paper
• Metabolic approach to heart failure: The role of metabolic modulators

  2015cites this paper
• Is Treatment with Trimetazidine Beneficial in Patients with Chronic Heart Failure?

  2014influential citation
• [Approaches potentiating cardioprotective effect of ambulatory physical training in patients with ischemic heart disease and multivessel coronary artery involvement after coronary stenting].

  2014cites this paper
• Metabolomics signature improves the prediction of cardiovascular events in elderly subjects.

  2014cites this paper
• Effects of trimetazidine in nonischemic heart failure: a randomized study.

  2014cites this paper
• Ultrasonic microdialysis coupled with capillary electrophoresis electrochemiluminescence study the interaction between trimetazidine dihydrochloride and human serum albumin.

  2014cites this paper
• Metabolic remodeling as a target preventing myocardial dysfunction: focus on trimetazidine

  2014cites this paper
• Clinical aspects and treatment of ischemic heart disease associated with COPD

  2014cites this paper
• Post-Genomic Analysis of Fatty Acid and Glucose Metabolism in Cardiovascular Disease

  2014cites this paper
• Modulation of Myocardial Metabolism by 3-Ketoacyl Coenzyme a Thiolase Inhibition and Other Agents in Heart Failure Treatment

  2014cites this paper
• Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine

  2014cites this paper
• Cardiac metabolism in hypertrophy and heart failure: implications for therapy

  2013cites this paper
• A “PET” area of interest: myocardial metabolism in human systolic heart failure

  2013cites this paper
• Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study.

  2013cites this paper
• New pharmacological targets in the treatment of heart failure: inhibition of free fatty oxidation by trimetazidine

  2012cites this paper
• Efficacy of Metabolic Modulators in Ischemic Heart Disease: An Overview

  2012cites this paper
• Targeting myocardial substrate metabolism in heart failure: potential for new therapies

  2012cites this paper
• Trimetazidine improves right ventricular function by increasing miR-21 expression.

  2012cites this paper
• Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.

  2012influential citation
• Evaluation of Anti-Ischemic Therapy in Coronary Artery Disease: A Review

  2012cites this paper
• Rôle de PGC-1α dans le système cardiovasculaire : recherche d’activateurs cœur-spécifiques et étude de ses mécanismes de régulation dans le muscle lisse aortique

  2012cites this paper
• PPAR/PGC-1 Regulation of Metabolism in Cardiac Disease

  2012cites this paper
• Structure dependence of long-chain [18F]fluorothia fatty acids as myocardial fatty acid oxidation probes.

  2012cites this paper
• Featured research Featured research Abstracts and commentaries Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts

  2012cites this paper
• The study of myocardial metabolism and its role in the pathophysiology of early diabetic cardiomyopathy

  2012cites this paper
• Trimetazidine Protects against Smoking-Induced Left Ventricular Remodeling via Attenuating Oxidative Stress, Apoptosis, and Inflammation

  2012cites this paper
• Metabolic therapy for heart failure including diastolic heart failure

  2012cites this paper
• New therapeutic approaches Metabolic modulation in dilated cardiomyopathy

  2011cites this paper
• Trimetazidine on ischemic injury and reperfusion in coronary artery bypass grafting.

  2011cites this paper
• Beneficial effects of trimetazidine (Vastarel ® MR) in patients

  2011cites this paper
• Optimization of Cardiac Metabolism in Heart Failure

  2011cites this paper
• Quality of life with trimetazidine

  2011cites this paper
• Evaluation of Trimetazidine in Angina Pectoris by Echocardiography and Radionuclide Angiography: A Meta‐Analysis of Randomized, Controlled Trials

  2011cites this paper
• Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure

  2011cites this paper
• New potential of Trimetazidine MB for coronary heart disease treatment in the real-world clinical practice : results of the Russian multi-centre randomised study PERSPECTIVE ( Part II )

  2011cites this paper
• Metabolic remodelling in human heart failure.

  2011cites this paper
• Modulating fatty acid oxidation in heart failure.

  2011cites this paper
• Lipotoxicity in Obesity and Coronary Artery Disease. Studies by PET, CT and MR

  2011cites this paper
• The clinical benefits provided by trimetazidine (Vastarel

  2011cites this paper
• Quality of life in chronic angina

  2011cites this paper
• Synthesis and Preliminary Evaluation of 18-18F-Fluoro-4-Thia-Oleate as a PET Probe of Fatty Acid Oxidation

  2010cites this paper
• The clinical benefits provided by trimetazidine (Vastarel® MR) in left ventricular dysfunction patients

  2010cites this paper
• Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease

  2010cites this paper
• Role of RAAS inhibition in preventing left ventricular remodeling in patients post myocardial infarction

  2010influential citation
• Demand-induced ischemia in volume expanded isolated rat heart; the effect of dichloroacetate and trimetazidine.

  2010cites this paper
• Trimetazidine: a meta-analysis of randomised controlled trials in heart failure

  2010cites this paper
• Vastarel MR: from decades of clinical experience in stable angina to new perspectives

  2010cites this paper
• [Heart energy metabolism and its role in the treatment of heart failure].

  2010cites this paper
• Clinical overview of trimetazidine (Vastarel MR) in patients with heart failure

  2010cites this paper